



# ASX Release

EMvision Medical Devices Ltd  
ACN 620 388 230  
Level 10, 12 Creek Street,  
Brisbane Qld 4000  
02 8667 5337  
contact@emvision.com.au

## CLEANSING NOTICE

EMVision Medical Devices Limited (ASX: EMV) (“**EMVision**” or the “**Company**”) confirms that it has issued 100,000 fully paid ordinary shares (Shares) pursuant to the exercise of 100,000 unlisted Series B options with a \$0.57 exercise price and 1 July 2022 expiry date. An Appendix 2A regarding the issue of these Shares has also been announced today.

### **Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Act”)**

The Act restricts the on-sale of securities issued without disclosure, unless the sale is exempt under section 708 or 708A of the Act. By giving this notice, the Shares noted in the Appendix 2A will fall within the exemption in section 708A(5) of the Act.

The Company advises that:

- a) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- b) this notice is being given under sections 708A(5)(e) of the Corporations Act;
- c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) section 674 of the Corporations Act, as it applies to the Company; and
- d) as at the date of this notice, there is no information that is “excluded information” within the meanings of sections 708A(7) and 708A(8) of the Corporations Act.

The Company notes the Appendix 2A also includes the issue of a further 100,000 fully paid ordinary shares pursuant to the exercise of 100,000 unlisted Series A options with a \$0.35 exercise price and 31 December 2021 expiry date. These options were issued pursuant to the Lead Manager Offer in the IPO Prospectus.

This announcement was authorised for release by the Chairman of the Company.

Emma Waldon  
Company Secretary